Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olpadronate monosodium
- Development stage
- Unknown
- Lead developer
- Gador
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
IG-8801 (olpadronate monosodium) is a non-traditional bisphosphonate small molecule developed by the Argentine pharmaceutical company Gador S.A. Unlike classical bisphosphonates, IG-8801 does not inhibit osteoclast viability or function, nor does it inhibit the mevalonate pathway or bone resorption. Instead, it retains a high affinity for mineralized bone (hydroxyapatite) and has been shown to prevent the apoptosis of osteoblasts and osteocytes in vitro. The drug has been investigated in Phase 2 clinical trials as an intravenous treatment for chronic low back pain associated with degenerative lumbar spine disease. Historically, it has also been studied for the treatment of Paget's disease of bone and osteoporosis.
- Other names
- monosodium olpadronateolpadronic acid sodium saltolpadronate sodium
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on olpadronate monosodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olpadronate monosodium.